Det skulle anvendes til patienter, som ikke er egnede til intensiv kemoterapi, fordi de har visse genetiske anomalier i de myeloide celler, “ sekundær ” AML (AML efter en tidligere blodsygdom) eller en anden sygdom ud over AML, eller fordi de er 70 år eller ældre.
It was to be used in patients who are not suitable for intensive chemotherapy, because they have certain genetic abnormalities in their myeloid cells, ‘ secondary’ AML (AML following a previous blood disorder) or another disease in addition to AML, or because they are 70 years of age or older.